1255 GMT - Roche Holding struck an upbeat tone on its drug pipeline, but didn't deliver the guidance upgrade some expected, as it gave investors an update on its pharma business, RBC Capital Markets analysts say in a research note. The Swiss pharma group said Monday that it plans new studies for its breast-cancer drug candidate giredestrant across different treatment lines, combinations and settings of the disease. "While the breadth of the giredestrant program and broader pipeline provided encouragement around Roche's longer-term growth potential, the lack of midterm guidance update meant the event unlikely provided the incremental upside catalyst some investors had been hoping for," they add. Shares fall 1.2%.